Iterum Therapeutics Partners with Eversana for US Launch

Iterum Therapeutics ( (ITRM) ) has provided an announcement.

On June 6, 2025, Iterum Therapeutics US Limited entered into a Product Commercialization Agreement with EVERSANA Life Science Services for the commercialization of ORLYNVAHTM in the United States. Under this agreement, Eversana will handle sales, marketing, logistics, and other services, while ITUS retains legal and regulatory responsibilities. The agreement spans five years from the commercial launch of ORLYNVAHTM, with provisions for termination under specific conditions, impacting the company’s operational strategy and market presence.

The most recent analyst rating on (ITRM) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.

Spark’s Take on ITRM Stock

According to Spark, TipRanks’ AI Analyst, ITRM is a Underperform.

Iterum Therapeutics faces significant financial challenges with ongoing net losses and cash flow issues, despite positive developments such as FDA approval of ORLYNVAH. The technical indicators suggest weak market momentum, and valuation metrics reflect poor investment attractiveness. The potential market for ORLYNVAH and improved financial performance are notable positives, but strategic uncertainties and financial obligations weigh heavily on the stock’s outlook.

To see Spark’s full report on ITRM stock, click here.

More about Iterum Therapeutics

Iterum Therapeutics is a pharmaceutical company focused on developing and commercializing innovative anti-infectives. Its primary product, ORLYNVAHTM, is aimed at addressing unmet medical needs in the treatment of infections.

Average Trading Volume: 448,461

Technical Sentiment Signal: Sell

Current Market Cap: $41.6M

Find detailed analytics on ITRM stock on TipRanks’ Stock Analysis page.